EcoDrugPlus

Glycoprotein Vi Platelet

Ensembl ID : ENSGGOG00000006054
Gene Symbol: GP6
2 Cross references
135 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gonadotropin Releasing Hormone Receptor

Ensembl ID : ENSGGOG00000016163
Gene Symbol: GNRHR
2 Cross references
454 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSGGOG00000001291
Gene Symbol: GHRHR
2 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSGGOG00000024411
Gene Symbol: GHSR
2 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSGGOG00000011975
Gene Symbol: GUCY1A1
2 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSGGOG00000009726
Gene Symbol: GUCY1A2
2 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSGGOG00000007160
Gene Symbol: GUCY1B1
2 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSGGOG00000008889
Gene Symbol: HSP90AB1
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

High Mobility Group Box 1

Ensembl ID : ENSGGOG00000026764
Gene Symbol: HMGB1
2 Cross references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H2

Ensembl ID : ENSGGOG00000010675
Gene Symbol: HRH2
2 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H4

Ensembl ID : ENSGGOG00000005579
Gene Symbol: HRH4
2 Cross references
105 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 10

Ensembl ID : ENSGGOG00000014445
Gene Symbol: HDAC10
2 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).